BOSTON, Dec.11, 2025 – Lindus Health, the “anti-CRO” running radically faster, more
reliable clinical trials for life science pioneers, and Quotient Sciences, a leading global
clinical development and manufacturing accelerator, have announced a strategic partnership
to enable innovative biotech and pharma sponsors with enhanced patient recruitment for
Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-ofconcept
(POC) trials.
The drug development process has traditionally required companies to engage multiple
vendors across pre-clinical and clinical phases, creating inefficiencies, knowledge gaps, and
operational delays. Lindus Health and Quotient Sciences partnership directly addresses this
industry challenge by combining Quotient’s specialized early clinical and drug development
capabilities with Lindus’ proven patient recruitment expertise and later-stage trial delivery.
The outcome is a cohesive development continuum for customers, championed by trusted,
experienced partners who are agile and committed to accelerating the delivery of new
treatments to patients.
Quotient Sciences conducts more than 70 Phase I studies per year across its clinics in the
US and UK, specializing in FIH to POC programs and a range of clinical pharmacology
studies. The company’s unique Translational Pharmaceutics® model integrates drug product
development with early clinical capabilities, enabling rapid progression from formulation to
FIH. Early phase studies increasingly require specific patient populations, including
challenging cohorts that extend beyond traditional healthy volunteers. Through this
partnership, Lindus provides comprehensive patient recruitment support with an omnichannel
approach, access to over 40 million electronic medical records (EMRs), and a
widespread site network. Lindus Health has an established track record of delivering 73%
faster enrollment across all studies, enabling Quotient Sciences to execute efficient, highquality
Phase I-IIa trials involving patients.
Lindus Health brings extensive Phase II trial experience and end-to-end trial delivery
capabilities across the US, UK, and Europe, spanning multiple therapeutic areas, including
respiratory, neuropsychiatry, cardiometabolic, dermatology, and more. Together, the
companies offer a streamlined approach to clinical development, eliminating the need to
independently source and vet separate Phase I and later-stage CROs. The result is reduced
administrative burden, accelerated timelines, and more focus for sponsors on advancing
their science rather than managing vendors.
“This partnership underscores our commitment to removing bottlenecks in the clinical
development lifecycle,” said Michael Young, Co-CEO of Lindus Health. “By collaborating
with Quotient Sciences, we are creating a comprehensive development pathway that allows
biotech companies to move through a contiguous experience from FIH studies through to
pivotal trials. Sponsors get the specialized Phase I expertise they need at the beginning, with
recruitment support from the same proven end-to-end CRO partner ready to scale their
programs as they progress.”
“Early-phase programs increasingly demand patient cohorts and rapid iteration, and Quotient
is addressing this industry need. By pairing Lindus Health’s recruitment engine with our early
clinical development expertise and Translational Pharmaceutics® platform, sponsors can
move seamlessly from first-in-human into later-stage trials with fewer handoffs, clearer
decision-making, and materially shorter timelines,” said Matt Paterson, Chief Strategy
Officer, Quotient Sciences.
This collaboration is essential to eliminating traditional barriers in patient recruitment and
reducing friction when transitioning between development stages and CRO partners,
ultimately accelerating the delivery of breakthrough treatments to patients.